SPA
FDMT icon

Sherbrooke Park Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

Sherbrooke Park Advisers’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,578
Closed -$327K – 1005
2024
Q2 		$327K Buy
+15,578
New +$391K 0.06% 585

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sherbrooke Park Advisers's FDMT Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of 4D Molecular Therapeutics (FDMT) in Q3 2024, closing a stake of 15,578 shares — an estimated $327K sold.

Sherbrooke Park Advisers first reported a position in FDMT in Q2 2024 and held it in 1 quarter. The position peaked at $327K in Q2 2024. 140 funds tracked by Wall St. Rank hold FDMT as of Q3 2024.

  • Sherbrooke Park Advisers reported no remaining 4D Molecular Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 15,578 4D Molecular Therapeutics shares in Q3 2024, an estimated $327K.
  • Sherbrooke Park Advisers first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's 4D Molecular Therapeutics position peaked at $327K in Q2 2024.
  • 140 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.